On 11 July 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 67/2024 on the reimbursement coverage of the medicinal product Keytruda (pembrolizumab) within the framework of the drug program “Treatment of patients with endometrial cancer (ICD-10: C54)”
Publication in Public Information Bulletin (BIP) >>